Clinical Trial Update: PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a PDE4 inhibitor for seborrheic dermatitis and papulopustular rosacea was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papulopustular Rosacea
• Seborrheic Dermatitis

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Seborrheic Dermatitis, Papulopustular Rosacea | Phase 2 | Status: TERMINATED